Hospital Consultations in Hyponatremia: Appropriate Diagnosis and Effective Treatment to Improve Patient Outcomes: Carl, Margret

Title:

Hospital Consultations in Hyponatremia: Appropriate Diagnosis and Effective Treatment to Improve Patient Outcomes: Carl, Margret

Topic: Nephrology
Relevant Terms: Cardiovascular Diseases, Hyponatremia, SIADH
Primary Audience: Endocrinologists, Hospitalists, Nephrologists
Launch Date: 12-Jun-13
Credits: 0.5 AMA PRA Category 1 Credit
Expiration Date: The accreditation for this activity has expired.
Patients Seen:  Carl Margret
Curriculum Name: Hospital Consultations in Hyponatremia: Appropriate Diagnosis and Effective Treatment to...

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Diagnose hyponatremia in hospitalized patients appropriately based on the presenting signs and symptoms and lab results
  2. Incorporate  therapeutic agents that improve outcomes and minimize risk based on their ability to address the underlying pathophysiological problems in patients with hyponatremia

    Faculty

    Alpesh N. Amin, MD, MBA, MACP, SFHM
    Activity Leader
    Professor and Chair, Department of Medicine
    Executive Director of the Hospitalist Program
    University of California, Irvine
    Irvine, California
    Tomas Berl, MD
    Professor of Medicine
    Division of Renal Diseases and Hypertension
    University of Colorado
    School of Medicine
    Aurora, Colorado
    Gary L. Robertson, MD
    Emeritus Professor of Medicine
    Feinberg School of Medicine
    Northwestern University
    Chicago, Illinois
    Estimated time to complete the program: 30 minutes

    Program Overview
    Hyponatremia is regarded as the most common electrolyte disorder in clinical practice as it occurs in 15-40% of hospitalized patients and is estimated to be as high as 30-40% in patients admitted in the intensive care unit (ICU). An estimated 18-49% of patients admitted for cirrhosis have hyponatremia; 18-25% admitted for congestive heart failure (CHF) have hyponatremia; and 8-28% who have community acquired pneumonia have hyponatremia. Hyponatremia has been shown to cause neurological/neuromuscular symptoms, including gait disturbances, as well as osteoporosis. Of greater concern is its consistent association with increased risk of mortality during hospitalization though it is not clear if the hyponatremia is responsible for this mortality. Diagnosis and subsequent effective management of hyponatremia in patients is complex as the signs and symptoms that result from hyponatremia overlap with a number of other diseases or conditions. It has been reported that treatment of hyponatremia is often underprioritized. In addition to improper diagnosis, a recent report showed that a significant percentage of patients developed hyponatremia in the hospital, and in a small percentage of patients, hospitalization aggravated hyponatremia highlighting the fact that the disorder is not appropriately managed. Some patients develop hyponatremia only after being hospitalized for reasons that are unclear but are likely related to introduction of IV fluids. Additionally, traditional therapies (eg, fluid restriction) address only part of the pathophysiology of hyponatremia and are relatively ineffective as the inappropriate urinary concentration slows the rate of water loss necessary to restore serum sodium to normal. Thus, using 2 case-based presentations through RealCME's ConsultService, this educational activity will provide practical strategies that will enable the participants to effectively diagnose and manage patients with hyponatremia using appropriate pharmacological therapies that best address the underlying pathophysiological problems to improve outcomes while minimizing adverse events.

    Target Audience
    This activity has been designed to meet the educational needs of hospitalists, nephrologists, endocrinologists, and other healthcare professionals involved in the care of patients with hyponatremia.

    Program Agenda
    Case #1: Assessing and Managing a Patient with Cardiac Heart Failure with Signs and Symptoms of Hyponatremia
    Case #2: Assessing and Managing a Patient with SIADH with Signs and Symptoms of Hyponatremia

    Physician Continuing Medical Education
    Accreditation Statement
    This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and ACCELMED. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

    Credit Designation
    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    Alpesh N. Amin, MD, MBA, MACP, SFHM 
    Contracted Research:
    Otsuka America Pharmaceutical, Inc.

    Tomas Berl, MD
    Consulting Fees: sanofi-aventis

    Gary L. Robertson, MD
    Contracted Research:
    Otsuka America Pharmaceutical, Inc.

    The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

    The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
     
    The following ACCELMED planners and managers, Jason LeDune, MS, and James M. Westbrooks, PhD, hereby state that they or their spouses/life partners have no relationships with commercial interests.
     
    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period June 12, 2013 through June 12, 2014, participants must read the learning objectives and faculty disclosures and study the educational activity.  
     
    If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation following the activity. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.
     
    Media
    Internet

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.  
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Acknowledgement

     
    This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.